429 related articles for article (PubMed ID: 27103391)
1. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids.
Dekkers JF; Gogorza Gondra RA; Kruisselbrink E; Vonk AM; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
Eur Respir J; 2016 Aug; 48(2):451-8. PubMed ID: 27103391
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
[TBL] [Abstract][Full Text] [Related]
3. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Solomon GM; Marshall SG; Ramsey BW; Rowe SM
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
[TBL] [Abstract][Full Text] [Related]
5. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
[TBL] [Abstract][Full Text] [Related]
6. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
7. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.
Dekkers JF; Berkers G; Kruisselbrink E; Vonk A; de Jonge HR; Janssens HM; Bronsveld I; van de Graaf EA; Nieuwenhuis EE; Houwen RH; Vleggaar FP; Escher JC; de Rijke YB; Majoor CJ; Heijerman HG; de Winter-de Groot KM; Clevers H; van der Ent CK; Beekman JM
Sci Transl Med; 2016 Jun; 8(344):344ra84. PubMed ID: 27334259
[TBL] [Abstract][Full Text] [Related]
8. Rescue of CFTR NBD2 mutants N1303K and S1235R is influenced by the functioning of the autophagosome.
Liu Q; Sabirzhanova I; Yanda MK; Bergbower EAS; Boinot C; Guggino WB; Cebotaru L
J Cyst Fibros; 2018 Sep; 17(5):582-594. PubMed ID: 29936070
[TBL] [Abstract][Full Text] [Related]
9. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
[TBL] [Abstract][Full Text] [Related]
10. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM
Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
[TBL] [Abstract][Full Text] [Related]
11. PTI-801 (posenacaftor) shares a common mechanism with VX-445 (elexacaftor) to rescue p.Phe508del-CFTR.
Ferreira FC; Amaral MD; Bacalhau M; Lopes-Pacheco M
Eur J Pharmacol; 2024 Mar; 967():176390. PubMed ID: 38336013
[TBL] [Abstract][Full Text] [Related]
12. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
[TBL] [Abstract][Full Text] [Related]
13. Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.
Sinha C; Zhang W; Moon CS; Actis M; Yarlagadda S; Arora K; Woodroofe K; Clancy JP; Lin S; Ziady AG; Frizzell R; Fujii N; Naren AP
Chembiochem; 2015 Sep; 16(14):2017-22. PubMed ID: 26227551
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
[TBL] [Abstract][Full Text] [Related]
15. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
[TBL] [Abstract][Full Text] [Related]
16. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
[TBL] [Abstract][Full Text] [Related]
17. Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing.
Boinot C; Jollivet Souchet M; Ferru-Clément R; Becq F
J Pharmacol Exp Ther; 2014 Sep; 350(3):624-34. PubMed ID: 24970923
[TBL] [Abstract][Full Text] [Related]
18. Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants.
van Willigen M; Vonk AM; Yeoh HY; Kruisselbrink E; Kleizen B; van der Ent CK; Egmond MR; de Jonge HR; Braakman I; Beekman JM; van der Sluijs P
Life Sci Alliance; 2019 Feb; 2(1):. PubMed ID: 30659068
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein.
Spanò V; Barreca M; Cilibrasi V; Genovese M; Renda M; Montalbano A; Galietta LJV; Barraja P
Molecules; 2021 Feb; 26(5):. PubMed ID: 33652850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
